FARMACIA HOSPITALARIA最新文献

{"title":"[Translated article] Influence of age on the efficacy of immunochemotherapy in non-small cell lung cancer","authors":"Alicia Aguado-Paredes ,&nbsp;Laura Moñino-Dominguez ,&nbsp;Jaime Cordero-Ramos ,&nbsp;Emilio Alegre-Del-Rey","doi":"10.1016/j.farma.2025.10.007","DOIUrl":"10.1016/j.farma.2025.10.007","url":null,"abstract":"<div><h3>Objective</h3><div>There is uncertainty about how age affects the efficacy of immunotherapy due to the natural process of immunosenescence. The aim of this systematic review and meta-analysis is to assess whether age over 65 years affects the efficacy, in terms of overall survival, of immunotherapy treatments in combination with chemotherapy or double immunotherapy, used in first-line metastatic non-small cell lung cancer without molecular alterations.</div></div><div><h3>Methods</h3><div>A systematic review and meta-analysis were performed. A systematic search of PubMed and Cochrane Library until April 30, 2024 was conducted to identify randomized clinical trials comparing an experimental treatment with immune checkpoint inhibitors plus chemotherapy versus a platinum-based chemotherapy doublet in patients with locally advanced or metastatic non-small cell lung cancer, without molecular mutations and with any level of programmed death ligand 1 expression. The primary endpoint was the difference in efficacy between those older and younger than 65 years, measured in terms of difference in overall survival hazard ratio. We calculated the hazard ratio for overall survival with its 95% confidence interval in both age groups and assessed heterogeneity using an interaction test.</div></div><div><h3>Results</h3><div>A total of 1,505 publications were identified, of which 7 clinical trials were included. In addition, the European public report evaluating pembrolizumab in combination with platinum and nab-paclitaxel was incorporated. In total, the analysis included 5,572 patients: 2,893 under 65 years of age and 2,679 aged 65 years or older. The pooled Hazard Ratio for overall survival for patients in the first group was 0.68 (95% CI: 0.62–0.74), and for the second 0.77 (95% CI: 0.70–0.84). The p-interaction between the pooled Hazard Ratio of both groups was 0.0551.</div></div><div><h3>Conclusions</h3><div>Both those younger and older than 65 years benefit from immunotherapy combined with chemotherapy in the treatment of non-small cell lung cancer. Although there appears to be greater efficacy in those younger than 65 years, the influence of age is not entirely clear.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 1","pages":"Pages T57-T63"},"PeriodicalIF":1.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145445983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extravasaciones de fármacos no citotóxicos: encuesta sobre la participación del farmacéutico en los hospitales españoles","authors":"Inés Jiménez-Lozano ,&nbsp;Jose Manuel Caro-Teller ,&nbsp;Montserrat Pérez-Encinas ,&nbsp;Helena Esteban Cartelle ,&nbsp;Juan Manuel Rodríguez-Camacho ,&nbsp;María José Fernández-Megía ,&nbsp;Sergio Plata Paniagua ,&nbsp;María José Otero","doi":"10.1016/j.farma.2025.06.011","DOIUrl":"10.1016/j.farma.2025.06.011","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to evaluate the involvement of hospital pharmacists in the protocolization, management and clinical follow-up of non-cytotoxic drug extravasations in Spanish hospitals.</div></div><div><h3>Methods</h3><div>A survey was distributed through the SEFH email list using the REDCap® web platform. The characteristics of the participating hospitals, the availability of a protocol for managing non-cytotoxic drug extravasations, the healthcare professionals involved in developing the protocol, and the pharmacists' involvement and clinical follow-up in response to these incidents were investigated.</div></div><div><h3>Results</h3><div>A total of 89 complete responses were obtained from hospitals across 14 Autonomous Communities. Only 12 centers (13.5%) had a protocol that included recommendations for the extravasation of non-cytotoxic drugs, and in 11 (91.7%) of these, the pharmacist had participated in its development. The recommendations for extravasation management were mainly based on intrinsic drug properties such as pH and osmolarity, specific properties like vasoconstrictor drugs, or the classification of drugs as vesicants, irritants, or non-irritants. Wide variability was observed in recommendations regarding the application of cold or heat and hyaluronidase dosage. The decision to consult with pharmacy service regarding the management of extravasation depended largely on the individual nurse or physician's judgment, but 20 centers (22.5%) reported that they never received such consultations. A large proportion of Pharmacy Services (73.0%) reported that they participate in extravasation management by providing information by telephone, but 21 centers (23.6%) indicated that the pharmacist never participates in these adverse events. Limited involvement was also noted in the clinical assessment of the patient, follow-up of the extravasation, and documentation in the patient's medical history.</div></div><div><h3>Conclusion</h3><div>The results of this survey reflect the limited standardization in the management of non-cytotoxic drug extravasations, as well as significant heterogeneity in the level of involvement of hospital pharmacists in these adverse events across hospitals in our country. The need to establish a national guideline or document on the management of non-cytotoxic drug extravasations is highlighted, along with the importance of promoting interdisciplinary collaboration to improve patient safety.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 1","pages":"Pages 31-37"},"PeriodicalIF":1.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144620794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy in advanced endometrial cancer with microsatellite instability: A systematic review","authors":"Cristina Moreno-Ramos ,&nbsp;Manuel David Gil-Sierra ,&nbsp;María del Pilar Briceño-Casado","doi":"10.1016/j.farma.2025.05.008","DOIUrl":"10.1016/j.farma.2025.05.008","url":null,"abstract":"<div><h3>Background</h3><div>Endometrial cancer with microsatellite instability (MSI) involves 30% of diagnosed cases. There are some uncertainty about second-line treatment, after platinum-based first-line treatment. The aim of this study was to perform a systematic review on the scientific evidence of immunotherapies for endometrial cancer with MSI.</div></div><div><h3>Methods</h3><div>PubMed and Embase databases were searched up to May 28, 2024. We included clinical trials about patients with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H) diagnosed with advanced and/or metastatic endometrial cancer who had previously received platinum-based chemotherapy. Clinical trials with a dMMR or MSI-H population size of less than 10 patients were discarded. Efficacy results in overall survival, progression-free survival and objective response rate were used to determine the most interesting drugs. A safety analysis of therapies was developed.</div></div><div><h3>Results</h3><div>Fifty-four studies were found in a systematic search. Fourteen clinical trials were selected. The following drugs were evaluated: pembrolizumab monotherapy, pembrolizumab plus lenvatinib, durvalumab, durvalumab-tremelimumab combination, dostarlimab, nivolumab and avelumab. The greatest numerical efficacy effect was achieved by pembrolizumab, followed by pembrolizumab in combination with lenvatinib. The most common adverse events were fatigue and gastrointestinal disorders.</div></div><div><h3>Conclusion</h3><div>The efficacy of pembrolizumab and pembrolizumab-lenvatinib regimen appears promising. However, studies with larger sample size, longer follow-up and comparative design with subgroup analysis based on differences in microsatellite repair mechanisms are needed for proper therapeutic positioning.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 1","pages":"Pages 47-56"},"PeriodicalIF":1.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144545429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reducción del reenvasado innecesario como medida de sostenibilidad ambiental","authors":"David García-Martínez ,&nbsp;Manuela Martínez-Camacho ,&nbsp;Aida Rueda-Naharro ,&nbsp;David García-Marco","doi":"10.1016/j.farma.2025.05.005","DOIUrl":"10.1016/j.farma.2025.05.005","url":null,"abstract":"<div><h3>Objective</h3><div>The main objective is to describe the project and evaluate the impact of replacing repackaged medications with unit dose presentations in 15 public hospitals within a regional health system. Secondary objectives include identifying differences in the changes implemented across the 15 audited hospitals and conducting an exploratory analysis of the potential impact in other non-audited centers that requested participation in the project.</div></div><div><h3>Method</h3><div>A database containing over 2,000 medications available in unit dose format was developed and is updated monthly. In parallel, an automated system based on decision-making algorithms was implemented to identify improvement opportunities in medication procurement. The system was adopted either individually by hospitals or through centralized structures at the regional or private level. The analysis included data from 15 public hospitals, where the reduction in repackaging and its environmental, economic, and operational impact were assessed by measuring material, time, and cost savings. The results were subsequently extrapolated to the 172 hospitals that applied.</div></div><div><h3>Results</h3><div>In the 15 monitored hospitals, repackaging of approximately 1.27 million tablets per year was avoided, resulting in estimated savings of 17,016 km of packaging material, 866 kg in weight, and 113,693 min of labor. The avoided costs in materials and machinery amounted to 36,274€ annually. No statistically significant differences were observed in project adoption across the hospitals (<em>p</em> = 0.234). The extrapolation to 172 hospitals suggests a potential impact of 16.67 million tablets no longer requiring repackaging per year, with an estimated savings of 2220.13 km of material, 24,723 h of labor, and 451,768€ annually.</div></div><div><h3>Conclusions</h3><div>Replacing repackaged medications with commercially available unit dose formats significantly reduced material consumption, labor time, and repackaging-related costs in the evaluated hospitals. The implementation of the project was consistent across the 15 monitored hospitals. Furthermore, the model proved to be scalable. The main limitation identified was the limited availability of unit dose medications on the market; therefore, it is recommended to prioritize their inclusion in procurement processes and to promote their development by the pharmaceutical industry.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 1","pages":"Pages 43-46"},"PeriodicalIF":1.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diseño del plan de acogida al paciente (onboarding) en una unidad multidisciplinar de asma grave","authors":"Hilario Martínez-Barros ,&nbsp;María Muñoz-García ,&nbsp;Darío Antolín-Amérigo ,&nbsp;Silvia Sánchez-Cuéllar ,&nbsp;Ana Morales-Tirado ,&nbsp;Ana de-Andrés-Martín ,&nbsp;Gonzalo de-los-Santos-Granados ,&nbsp;Laura Yeguas-Ramírez ,&nbsp;Enrique Blitz-Castro ,&nbsp;Alfonso Santamaría-Gadea ,&nbsp;Belén de-la-Hoz-Caballer ,&nbsp;Sagrario Martín-Aragón ,&nbsp;David González-de-Olano ,&nbsp;Ana María Álvarez-Díaz","doi":"10.1016/j.farma.2025.07.003","DOIUrl":"10.1016/j.farma.2025.07.003","url":null,"abstract":"<div><h3>Objetives</h3><div>To design the patient onboarding in a multidisciplinary severe asthma unit, according to the needs identified by patients and professionals in the unit.</div></div><div><h3>Methods</h3><div>Qualitative study using the human-centred design conducted between November 2022 and February 2023. Patients and professionals from the severe asthma unit and experts in the methodology participated. Three workshops were held. In the first, we elaborated the patient experience map, identifying positive aspects and needs. Possible solutions were devised. In the second, we selected the solutions described in a previous project applicable to onboarding and determined the key moments. In the third, we finalised the definition of the key moments, the professionals in charge in each step and the tools to be incorporated. Finally, in short sessions (sprints) we developed the necessary material and infographics.</div></div><div><h3>Results</h3><div>We identified the main needs of patients (better control of the disease and autonomy in care, two-way conversation with professionals and receiving coordinated and personalised care) and professionals (defining, structuring, unifying and adapting the information provided to patients and managing to maintain open conversations with them). We determined that onboarding should establish a controlled welcome to the severe asthma unit, which is identifiable by patients, promotes the patient-professional relationship and the learning, use and functioning of the severe asthma unit.</div><div>Previously devised solutions applicable to onboarding, such as the landing kit or the patient diary, were selected. We established the key moments of onboarding (identification consultation, initial consultation, onboarding consultation and complementary consultations), the professionals involved and the necessary information, material and infographics.</div><div>Finally, we developed the design, structure and final content of the necessary tools, such as the patient diary or the asthma infographic.</div></div><div><h3>Conclusions</h3><div>This work has allowed us to design, structure and standardise the onboarding, providing an environment that facilitates self-care and open, empathetic, two-way conversation between patients and professionals, according with the key needs expressed by both. These findings may be useful for other multidisciplinary care units.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 1","pages":"Pages 16-22"},"PeriodicalIF":1.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diseño y validación del índice de fragilidad IF-CSS basado en la valoración geriátrica integral para su aplicación en centros sociosanitarios","authors":"Juan Francisco Peris-Martí ,&nbsp;Elia M. Fernández-Villalba ,&nbsp;Patricia Bravo-José ,&nbsp;Carmen Isabel Sáez-Lleó ,&nbsp;Minerva Espert-Roig ,&nbsp;Pilar Martínez-Antequera","doi":"10.1016/j.farma.2025.06.002","DOIUrl":"10.1016/j.farma.2025.06.002","url":null,"abstract":"<div><h3>Objective</h3><div>To validate the IF-CSS frailty index according to its predictive capacity for mortality and to define the intervals compatible with frailty states.</div></div><div><h3>Methods</h3><div>An observational, retrospective, multicenter study of a cohort of elderly patients from four nursing homes with a follow up between 12 and 38 months was conducted. The IF-CSS comprised 17 variables across four domains from the comprehensive geriatric assessment. Contrast of hypothesis log-rank for survival curves according to IF-CSS index was performed. The predictive model of survival time was performed using a parametric accelerated failure model.</div></div><div><h3>Results</h3><div>535 patients with a mean age of 83.62 years (DE±<!--> <!-->7.84) were included. Mortality rate during the study period was 39.8%. Survival curves by frailty intervals showed significant differences (<em>χ</em>² = 92; <em>p</em> &lt; 0.001). The comparative analysis also showed significant differences for almost all the variables included in the construct. The parametric model of accelerated failure estimated a 29% reduction in survival time for each tenth of an increase in the IF-CSS.</div></div><div><h3>Conclusions</h3><div>The IF-CSS results in a tool with a frailty discriminative and mortality predictive capacity that allows its use in the care programs of nursing homes.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 1","pages":"Pages 23-30"},"PeriodicalIF":1.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144620793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Reduction of unnecessary repackaging as an environmental sustainability measure","authors":"David García-Martínez ,&nbsp;Manuela Martínez-Camacho ,&nbsp;Aida Rueda-Naharro ,&nbsp;David García-Marco","doi":"10.1016/j.farma.2025.10.012","DOIUrl":"10.1016/j.farma.2025.10.012","url":null,"abstract":"<div><h3>Objective</h3><div>The main objective is to describe the project and evaluate the impact of replacing repackaged medications with unit dose presentations in 15 public hospitals within a regional health system. Secondary objectives include identifying differences in the changes implemented across the 15 audited hospitals and conducting an exploratory analysis of the potential impact in other non-audited centers that requested participation in the project.</div></div><div><h3>Method</h3><div>A database containing over 2,000 medications available in unit dose format was developed and is updated monthly. In parallel, an automated system based on decision-making algorithms was implemented to identify improvement opportunities in medication procurement. The system was adopted either individually by hospitals or through centralized structures at the regional or private level. The analysis included data from 15 public hospitals, where the reduction in repackaging and its environmental, economic, and operational impact were assessed by measuring material, time, and cost savings. The results were subsequently extrapolated to the 172 hospitals that applied.</div></div><div><h3>Results</h3><div>In the 15 monitored hospitals, repackaging of approximately 1.27 million tablets per year was avoided, resulting in estimated savings of 17,016 km of packaging material, 866 kg in weight, and 113,693 min of labor. The avoided costs in materials and machinery amounted to 36,274€ annually. No statistically significant differences were observed in project adoption across the hospitals (<em>p</em> = 0.234). The extrapolation to 172 hospitals suggests a potential impact of 16.67 million tablets no longer requiring repackaging per year, with an estimated savings of 2220.13 km of material, 24,723 h of labor, and 451,768€ annually.</div></div><div><h3>Conclusions</h3><div>Replacing repackaged medications with commercially available unit dose formats significantly reduced material consumption, labor time, and repackaging-related costs in the evaluated hospitals. The implementation of the project was consistent across the 15 monitored hospitals. Furthermore, the model proved to be scalable. The main limitation identified was the limited availability of unit dose medications on the market; therefore, it is recommended to prioritize their inclusion in procurement processes and to promote their development by the pharmaceutical industry.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 1","pages":"Pages T43-T46"},"PeriodicalIF":1.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contribución del metabolito N-óxido en la monitorización terapéutica de voriconazol en un paciente con aspergilosis invasiva","authors":"Irene Orozco Cifuentes,&nbsp;Adrián Domínguez García,&nbsp;María Jiménez Meseguer,&nbsp;Elena García Benayas,&nbsp;Benito García Díaz","doi":"10.1016/j.farma.2025.05.012","DOIUrl":"10.1016/j.farma.2025.05.012","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 1","pages":"Pages 64-66"},"PeriodicalIF":1.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Evaluation of penicillin allergy labeling in the emergency department: Retrospective study on the impact of a hospital pharmacist-led intervention algorithm","authors":"Fernando Salazar González ,&nbsp;Mireia Iglesias Rodrigo ,&nbsp;Gemma Garreta Fontelles ,&nbsp;Mireia Mensa Vendrell ,&nbsp;Jordi Nicolás Picó","doi":"10.1016/j.farma.2025.10.002","DOIUrl":"10.1016/j.farma.2025.10.002","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the impact of an intervention algorithm on penicillin allergy label reassessment in emergency department patients, aiming to optimize antibiotic selection and improve patient safety.</div></div><div><h3>Methods</h3><div>A retrospective observational study was conducted in a 450-bed hospital, including adult patients with a penicillin allergy label admitted to the emergency department between November 2023 and August 2024. An algorithm developed by the pharmacy service in collaboration with the ASP team was applied, based on validated tools such as the Penicillin Allergy De-Labelling Toolkit, PEN-FAST, and Antibiotic Allergy Assessment Tool. Demographic data, allergy history, and clinical outcomes were collected. The acceptance of recommendations and the incidence of adverse reactions were analyzed.</div></div><div><h3>Results</h3><div>A total of 66 patients were evaluated. Delabeling was proposed in 35 (53.03%) patients, skin testing in 13 (19.69%), oral provocation testing in 9 (13.63%), and label maintenance in 9 (13.63%). A total of 89.39% of the recommendations were accepted, achieving effective delabeling in 42 patients. No adverse reactions were recorded. In 21 cases, antibiotic therapy was optimized following the intervention.</div></div><div><h3>Conclusions</h3><div>The implementation of a structured algorithm for penicillin allergy reassessment in emergency settings is both effective and safe. Its application facilitates antibiotic optimization, improves patient safety, and reduces broad-spectrum antibiotic use. This study highlights the role of hospital pharmacists in drug allergy management and antimicrobial stewardship.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 1","pages":"Pages T10-T15"},"PeriodicalIF":1.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145757852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Achievements and challenges ahead for the journal Farmacia Hospilataria","authors":"Teresa Bermejo Vicedo,&nbsp;Maria Queralt Gorgas,&nbsp;Luis Margusino Framiñan","doi":"10.1016/j.farma.2025.11.009","DOIUrl":"10.1016/j.farma.2025.11.009","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 1","pages":"Pages T1-T2"},"PeriodicalIF":1.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}